Boston Bioprocess and Cauldron today announce their partnership which aims to overcome one of the biggest challenges for fermentation-based companies today – economically viable paths to scale from lab to manufacturing.

Boston Bioprocess and Cauldron will work together to create a path to industrial-scale production for companies that would benefit from Cauldron’s continuous fermentation technology.

Cauldron CEO and Co-founder, Michele Stansfield, said “Cauldron and Boston Bioprocess’s partnership supports the ecosystem, bringing together Boston Bioprocess’s best in class process development capabilities with Cauldron’s manufacturing expertise and hyper-fermentation technology.”.

“Together Cauldron and Boston Bioprocess are helping to bridge the valley of death for biotech companies who struggle to make the technology transition from lab to manufacturing.” said Ms Stansfield.

Boston Bioprocess CEO Michael Tai, PhD said the Cauldron and Boston Bioprocess partnership is about finding the best possible combination of technology and assets for each client.

"Transitioning to industrial-scale production is about finding the best partner for a client’s particular strain and particular product. It’s not a one-size-fits-all process, which means that we need to work hard to form a network of talented and reliable CMOs, all of whom can be the best fit for some portion of our client base,” said Dr. Tai.

“Working more closely with Cauldron allows us to minimize the pain of tech transfer and shorten the time to market for those clients that could benefit from Cauldron’s assets and unique technology,” Dr. Tai said.